Evidence map›Paper›PMID 33043467›Full record

ArticleAllergy2021

Butyrate as a bioactive human milk protective component against food allergy.

Lorella Paparo, Rita Nocerino, Elena Ciaglia, Carmen Di Scala, Carmen De Caro, Roberto Russo, Giovanna Trinchese, Rosita Aitoro, Antonio Amoroso, Cristina Bruno and 13 more

Open access · greenAbstract read
In one paragraph

Article in Allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 1 country.

Lorella PaparoDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.ORCID 0000-0002-5562-1408
Rita NocerinoDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.ORCID 0000-0003-4681-546X
Elena CiagliaDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Fisciano, Italy.
Carmen Di ScalaDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.
Carmen De CaroDepartment of Pharmacy, University of Naples Federico II, Naples, Italy.
Roberto RussoDepartment of Pharmacy, University of Naples Federico II, Naples, Italy.
Giovanna TrincheseDepartment of Biology, University of Naples Federico II, Naples, Italy.
Rosita AitoroDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.ORCID 0000-0002-8518-2047
Antonio AmorosoDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.
Cristina BrunoDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.
Margherita Di CostanzoDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.
Annalisa PassarielloDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.
Francesco MessinaNeonatal Intensive Care Unit, "Betania" Evangelical Hospital, Naples, Italy.
Annalisa AgangiNeonatal Intensive Care Unit, "Betania" Evangelical Hospital, Naples, Italy.
Marcello NapolitanoNeonatal Intensive Care Unit, "Betania" Evangelical Hospital, Naples, Italy.
Luana VotoDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.
Giusy Della GattaDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.
Laura PisapiaDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.
Francesco MontellaDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Fisciano, Italy.
Maria Pina MollicaDepartment of Biology, University of Naples Federico II, Naples, Italy.
Antonio CalignanoDepartment of Pharmacy, University of Naples Federico II, Naples, Italy.
Annibale PucaEuropean Laboratory for the Investigation of Food-Induced Diseases, University of Naples Federico II, Naples, Italy.
Roberto Berni CananiDepartment of Translational Medical Science, University of Naples Federico II, Naples, Italy.ORCID 0000-0002-5169-9574
University of Naples Federico II · ITCeinge Biotecnologie Avanzate (Italy) · ITRegione Campania · ITUniversity of Salerno · ITFederico II University Hospital · ITMultiMedica · ITOspedale Monaldi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFood allergy (FA) is a growing health problem worldwide. Effective strategies are advocated to limit the disease burden. Human milk (HM) could be considered as a protective factor against FA, but its mechanisms remain unclear. Butyrate is a gut microbiota-derived metabolite able to exert several immunomodulatory functions. We aimed to define the butyrate concentration in HM, and to see whether the butyrate concentration detected in HM is able to modulate the mechanisms of immune tolerance.

methodsHM butyrate concentration from 109 healthy women was assessed by GS-MS. The effect of HM butyrate on tolerogenic mechanisms was assessed in in vivo and in vitro models.

resultsThe median butyrate concentration in mature HM was 0.75 mM. This butyrate concentration was responsible for the maximum modulatory effects observed in all experimental models evaluated in this study. Data from mouse model show that in basal condition, butyrate up-regulated the expression of several biomarkers of gut barrier integrity, and of tolerogenic cytokines. Pretreatment with butyrate significantly reduced allergic response in three animal models of FA, with a stimulation of tolerogenic cytokines, inhibition of Th2 cytokines production and a modulation of oxidative stress. Data from human cell models show that butyrate stimulated human beta defensin-3, mucus components and tight junctions expression in human enterocytes, and IL-10, IFN-γ and FoxP3 expression through epigenetic mechanisms in PBMCs from FA children. Furthermore, it promoted the precursors of M2 macrophages, DCs and regulatory T cells.

conclusionThe study's findings suggest the importance of butyrate as a pivotal HM compound able to protect against FA.

Indexed as

Food HypersensitivityGastrointestinal MicrobiomeAnimalsButyratesImmune ToleranceMilk, HumanButyratesbreast milkimmune toleranceshort-chain fatty acidstolerogenic mechanism

Identifiers

PMID33043467
PMCPMC8247419
OpenAlexW3092494237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.